We analyzed whether Smad4 might serve as a marker of metastatic progression that could differentiate the aggressive Pten/Rb-null PC model from the indolent Akap12/Rb-null HG-PIN model. This evidence concerns the gene RB1 and prostate intraepithelial neoplasia.